http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22786418

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't
endingPage 1629
issn 1556-0864
issueIdentifier 10
pageRange 1623-1629
publicationName Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
startingPage 1623
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_641b27c856ab6d93f4a5ff87e1dbeea3
bibliographicCitation Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA. Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010 Oct;5(10):1623–9. doi: 10.1097/jto.0b013e3181ec1531.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75cc22d8dd1ff7e2307bec0027d680f1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_64f1d7b13a853ae988366ceb4059ae46
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2270e3ace0c5ca2e581a13ac0a79b84
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75df2e418a218b000200655595610026
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27f0d846d0a580a52d2ad7cc7a62171b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_14b4f28392fbdfa9a18599cfad35eeca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b65b312652d21187d3c0d5ee5896f4e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38ce68ddae8779e66beed0091e95315a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a1d4cc302b03e6ec59e3f08ecf3233a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee5afcab92401cedd68336557f9f46e6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b15545f0a9fb8aaef1dbdabbae26e29
date 201010
identifier https://pubmed.ncbi.nlm.nih.gov/PMC4020424
https://doi.org/10.1097/jto.0b013e3181ec1531
https://pubmed.ncbi.nlm.nih.gov/20871262
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33311
https://portal.issn.org/resource/ISSN/1556-0864
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
discusses http://id.nlm.nih.gov/mesh/M0024891
http://id.nlm.nih.gov/mesh/M0444984
http://id.nlm.nih.gov/mesh/M0017909
http://id.nlm.nih.gov/mesh/M0593322
http://id.nlm.nih.gov/mesh/M0500817
http://id.nlm.nih.gov/mesh/M0029863
http://id.nlm.nih.gov/mesh/M0027924
http://id.nlm.nih.gov/mesh/M0018336
http://id.nlm.nih.gov/mesh/M0301174
http://id.nlm.nih.gov/mesh/M000602394
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D002294Q000188
http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D008175Q000188
http://id.nlm.nih.gov/mesh/D000230Q000188
http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000077156
http://id.nlm.nih.gov/mesh/D011799Q000008
http://id.nlm.nih.gov/mesh/D002294Q000235
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D009154Q000235
http://id.nlm.nih.gov/mesh/D016283
http://id.nlm.nih.gov/mesh/D017321
http://id.nlm.nih.gov/mesh/D002289Q000235
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D020123Q000031
http://id.nlm.nih.gov/mesh/D066246Q000235
http://id.nlm.nih.gov/mesh/D020123Q000008
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D015331
http://id.nlm.nih.gov/mesh/D008175Q000235
http://id.nlm.nih.gov/mesh/D000230Q000235
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D008175Q000473
http://id.nlm.nih.gov/mesh/D000230Q000473
http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D002294Q000473
http://id.nlm.nih.gov/mesh/D009367
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D015996
http://id.nlm.nih.gov/mesh/D000068338
http://id.nlm.nih.gov/mesh/D018631Q000235
http://id.nlm.nih.gov/mesh/D011518Q000235
http://id.nlm.nih.gov/mesh/D002289Q000473
http://id.nlm.nih.gov/mesh/D016879
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284616
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6442177
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629

Total number of triples: 93.